Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flex-5 OTC switch candidate?

This article was originally published in The Tan Sheet

Executive Summary

Switch of Rx muscle relaxant Flexeril (cyclobenzaprine HCl) could be closer following Feb. 4 approval of less-sedating 5 mg dose for relief of muscle spasm associated with acute musculoskeletal pain. Efficacy of Flexeril 5 was demonstrated in two seven-day, double-blind, randomized, multi-center trials that showed the drug provided significant relief compared to placebo and caused "significantly less drowsiness than patients taking the 10 mg tablet," product marketer McNeil reports Feb. 4. Affiliated firm J&J/Merck has said the drug could be a switch candidate "some years down the road" (1"The Tan Sheet" Sept. 30, 2002, p. 3). The original 10 mg dose was the subject of a 1999 NDAC meeting, but committee members expressed concerns about patients' ability to accurately self-select for the drug...

You may also be interested in...

Mevacor, Ditropan Switch Discussions With FDA Proceeding Well – J&J

Discussions between FDA and J&J/Merck over the potential Rx-to-OTC switch of cholesterol-reducing statin Mevacor have been moving in a positive direction, J&J Consumer Pharmaceuticals & Nutritional Products Worldwide Chairman Brian Perkins reported

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts